In the United States, psilocybin mushrooms are the most widely used psychedelic substance. This finding comes from the latest report on psychedelic substances by the American think tank RAND (Research and Development). The research team, led by Beau Kilmer, conducted a national survey to assess the prevalence and usage of psilocybin-based products. The survey included responses from 3,791 American adults, who were asked about their habits regarding various drugs. According to the survey, 12 percent of respondents had used the hallucinogen at least once in their lifetime, while 3.1 percent had used it in the past 12 months. Estimates suggest that in 2023, at least eight million American adults may have used psilocybin. Psilocybin-based products are becoming increasingly popular in the West, partly due to their promising potential in treating various mental health conditions. However, this study focused on the use and distribution of psychedelics for non-clinical purposes.

An uncontrolled expansion of non-clinical psychedelic supply could generate a negative reaction, causing disruptions and limitations on therapeutic uses.

The researchers also analyzed data from the National Survey on Drug Use and Health and the National Incident-Based Reporting System. They interviewed legal experts, policy advocates, regulators, clinical researchers, mental health professionals, and representatives of organizations active in the emerging psychedelic sector. “Regulatory changes,” said Michelle Priest, another author of the report, “could affect indigenous populations with long traditions of using certain spiritual medicines commonly referred to as psychedelics. It would be more appropriate to respectfully involve community members who use these substances.” To mitigate the risks associated with psilocybin supply, experts suggest allowing personal harvesting or cultivation, as well as participation in non-profit collectives or cooperatives.

The report also found that those who use hallucinogens tend to do so sporadically, unlike with other drugs. For instance, 47 percent of participants who used psilocybin reported microdosing. “For cannabis,” commented Rajeev Ramchand, co-author of the report, “occasional users account for about five percent of total usage days in recent months, whereas for psychedelics, this figure reaches about 60 percent. This implies that price control, an important lever for other drugs, might have limited effects for psychedelics.”

Lascia un commento

Il tuo indirizzo email non sarà pubblicato. I campi obbligatori sono contrassegnati *